Adenovirus-mediated gene transfer of B7.1 induces immunological anti-tumor effects in a murine brain tumor

Journal of Neuro-Oncology

Volumn 60, Issue 1, 2002, Pages 13-23

  Morioka, Jun ^a   Kajiwara, Koji ^a   Yoshikawa, Koichi ^a   Ideguchi, Makoto ^a   Uchida, Tetsuya ^a   Ohmoto, Yoshinori ^a   Suzuki, Michiyasu ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

Adenoviral vector; B7.1 (CD80); Gene transfer; Glioma; Immune gene therapy

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA CELL; BRAIN TUMOR; CANCER GRAFT; CELL PROLIFERATION; CELL SURVIVAL; CODING; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; GENETIC TRANSFECTION; GLIOMA; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD80; ASTROCYTOMA; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MICE; NEOPLASM TRANSPLANTATION; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036794249     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020260822669     Document Type: Article

References (37)

1. Mathaley MS, Mettlin C, Natarajan N, Laws ER, Peace BB: National survey of patterns of care for brain-tumor patients. J Neurosurg 71: 826-836, 1989
2. Boon T: Toward a genetic analysis of tumor rejection antigen. Adv Cancer Res 58: 177-210, 1992
3. Hellström KE, Hellström I: Principles of tumor immunity: tumor antigen. The Biologic Therapy of Cancer. JP Lippincott Company, Philadelphia, 1991, p 35
4. + T-cell. J Exp Med 173: 759-762, 1991
5. Hathcock KS, Laszio G, Pucillo C, Linsley P, Hodes PJ: Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 180: 631-640, 1994
6. Morford AL, Dix RA, Brooke HW, Roszman LT: Apoptotic elimination of peripheral T-lymphocytes in patients with primary intracranial tumors. J Neurosurg 91: 935-946, 1999
7. Zou JP, Morford AL, Chougnet C, Dix RA, Brooks GA, Torres N, Shuman DJ, Coligan EJ, Brooke HM, Roszman LT, Shearer MG: Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 162: 4882-4892, 1999
8. Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn A, Peschanski MR: Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 3: 224-228, 1993
9. Bett AJ, Prevec L, Graham FL: Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67: 5911-5921, 1993
10. Rubin SA, Rorke LB: Adenoviral vaccines. In: Mortimer EA, Plotkin SA (eds) Vaccines. Sauders, Philadelphia, 1988, p 492
11. Boxhorn HK, Smith JG, Chang YJ, Guerry D, Lee WM, Rodeck U, Turka LA, Eck SL: Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors. Cancer Immunol Immunother 46: 283-292, 1998
12. Pützer MB, Hitt M, Muller JW, Emtage P, Gauldie J: Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 94: 10889-10894, 1997
13. Joki T, Kikuchi T, Akasaki Y, Saitoh S, Abe T, Ohno T: Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. Int J Cancer 82: 714-720, 1999
14. Byrnes AP, Rusby JE, Wood MJ, Charlton HM: Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66: 1015-1024, 1995
15. Graham FL, Smiley J, Russel WC, Nairn R: Characteristics of human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74, 1977
16. Matthews DE, Farewell VT: The log-Rank or Mantel-Haenszel test for comparison of survival curves. In: Using and Understanding Medical Statistics, 2nd edn. Karger, Basel, Switzerland, 1988, p 79
17. Springer TA: Cell-surface differentiation in the mouse. Characterization of 'jumping' and 'lineage' antigens using xenogenic rat monoclonal antibodies. In: Kenneth RH, McKearns TJ, Bechtol KB (eds) Monoclonal Antibodies. Plenum, New York, 1980, pp 185-217
18. Rabinowitz SS, Gordon S: Macrosialin, a macrophage-restricted membrane sialoprotein differentially glycosylated in response to inflammatory stimuli. J Exp Med 174: 827-836, 1991
19. Schwartz RH: A cell culture model for T-lymphocyte clonal energy. Science 248: 1349-1356, 1990
20. Radvanyi LG, Mills GB, Miller RG: Relegation of the T-cell receptor after primary activation of mature T-cells inhibits proliferation and induces apoptotic cell death. J Immunol 150: 5704-5715, 1993
21. Chen L, Ashe S, Brady AW, Hellström I, Hellström EK, Ledbetter AJ, McGowan P, Linsley SP: Costimulation of antitumor immunity by the B7 counterreceptor for the T-lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093-1102, 1992
22. + T-lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153: 421-428, 1994
23. Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM: A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 182: 1415-1421, 1995
24. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström EK: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179: 523-532, 1994
25. Wekerle H, Sun D, Oropeza-Wekerle RL, Meyermann R: Immune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. J Exp Biol 132: 43-57, 1987
26. Wong GH, Bartlett PF, Clark-Lewis I, Battye F, Schrader JW: Inducible expression of H-2 and Ia antigens on brain cells. Nature 310: 688-691, 1984
27. Yeh P: Efficient dural trans-complementation of adenovirus E1 and E4 region from 293-derived cell line expressing a minimal E4 function unit. J Virol 70: 559-565, 1996
28. Visted T, Thorsen J, Thorsen F, Read TA, Ulvestad E, Engebraaten O, Sorensen D, Yla-Herttuala S, Tyynela K, Rucklidge G, Edvardsen K, Bjerkvig R, Lund-Johansen M: LacZ-neoR transfected glioma cells in syngeneic rats: growth pattern and characterization of the host immune response against cells transplanted inside and outside the CNS. Int J Cancer 85: 228-235, 2000
29. Kajiwara K, Byrnes AP, Charlton HM, Wood MJA, Wood KJ: Immune responses to adenoviral vectors during gene transfer in the brain. Hum Gene Ther 8: 253-265, 1997
30. Chong H, Hutchinson G, Hart IR, Vile RG: Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. Hum Gene Ther 7: 1771-1779, 1996
31. Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182: 459-465, 1995
32. Emtage PC, Wan Y, Bramson JL, Graham FL, Gauldie J: A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J Immunol 160: 2531-2538, 1998
33. Salvadori S, Zier K: Gene therapy with modified tumor cells enables T-cell activation by stimulating pathway required for signal transduction. Cytokines Mol Ther 2: 171-175, 1996
34. Cayeux S, Beck C, Dorken B, Blankenstein T: Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther 7, 525-529, 1996
35. + T cells. J Immunother 20: 256-264, 1997
36. Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP: Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer 77: 107-113, 1998
37. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181: 619-629, 1995